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Amyloidogenic proteins are an important part of the constitution of our bodies; such 
examples, in humans alone, include their roles in peptide hormone storage, melanin 
biosynthesis and neural growth and repair, to name just a few.1 A key step in the growth 
and formation of amyloid fibrils is elongation, the addition of protein monomers to the fibril 
ends.  However, it is currently thought that this process can result in the formation of 
cytotoxic oligomers which, in vivo, can lead to neurodegenerative diseases. This research 
focused on synthesising two chemical linkers in order to conjugate a known amyloid-forming 
protein of interest with a strand of deoxyribose nucleic acid (DNA). As a result, it was hoped 
the effect of DNA on amyloid fibrils could be investigated, with the extent to which amyloid 
formation could be influenced and controlled explored, and thus the toxicity of the oligomers 
examined.  Amyloid also have many material applications and hence the potential use of 
the materials in which these templated amyloid could be used could also be studied.    
 
The first linkers to be made were maleimide chemical linkers, N-(6-acetamidopyridin-y-yl)-
2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamide (linker 1A) and N-6-acetamidopyridin-
yl-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide (linker 1B). Synthesis of linker 1A 
proved challenging, but linker 1B led to more positive results. After synthesis and 
characterisation, the conjugation with the protein and DNA was carried out; the formation 
of the conjugates was validated using ultra-violet visible spectrometry, mass spectrometry, 
gel electrophoresis and amyloid formation assays using a fluorescent probe.   
 
The second linkers produced were also maleimide linkers, 6-maleimidohexanoic acid N-
hydroxysuccinimide ester (linker 2A) and 2-cyanoethyl 2-((3aR,4S,7aS)-4,7-dimethyl-1,3-
dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2yl)ethyl)diiospropylphosphoramidite 
(linker 2B). Conjugation to the DNA followed, with linker 2A conjugated successfully using 
a solution-based method, and thus the addition of the protein to the linker-DNA compound; 
likewise to linker 1B, the conjugation was monitored using ultra-violet-visible spectrometry, 
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mass spectrometry, gel electrophoresis and analysis of 96 well microplates. Conversely, 
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%    =  Percentage 
ºC   =  Degrees Celsius 
µL   =  Microlitre 
µM   =  Micromolar 
Ac   = Acetyl 
AFM    = Atomic force microscopy 
C   = Cysteine 
CDCl3   = Chloroform 
Da   = Daltons 
DMAP   = 4-dimethylamino pyridine 
DCM   = Dichloromethane 
DMF   = Dimethylformamide 
DMSO   = Dimethyl sulfoxide  
DNA    = Deoxyribose nucleic acid 
DTT   = Dithiothreitol 
EDC.HCl  =  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide  
   hydrochloride 
ESI   = Electrospray 
Et3N   = Triethylamine 
EtOAc   = Ethyl acetate 
F   =  Phenylalanine 
G    = Gravity 
g   = Grams 
G   = Glycine 
GdnHCl  = Guanidine hydrochloride 
H   = Histidine 
HATU   = Hexafluorophosphate azabenzotriazole tetramethyl uranium  
     (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazole[4,5-  
     b]pyridinium-3-oxide-hexafluorophashpahte) 
 8 
HFIP   = Hexafluoroisopropanol 
HPLC    = High performance liquid chromatography 
I   = Isoleucine 
K   = Lysine 
LC-MS   =  Liquid chromatography mass spectrometry 
LCys   = Linker cysteine 
M   = Methionine 
MALDI-TOF MS = Matrix-assisted laser desorption ionisation time-of-flight 
mg   = Milligrams 
MHz    =  Megahertz 
mL   =  Millilitre 
mM   = Millimolar 
Mol equiv  = Molar equivalent 
MS    =  Mass spectrometry 
MW   =  Molecular weight 
m/z   = Mass to charge ratio 
N   = Asparagine 
NaCl   = Sodium chloride 
N-Boc Gly  = N-(tert-butoxycarbonyl)glycine 
ppm   = Parts per million 
R   = Arginine 
S   = Serine 
TCEP   = Tris(2-carboxyethyl)phosphine 
TFA   = Trifluoroacetic acid 
THF    = Tetrahydrofuran 
ThT   =  Thioflavin T 
TIPS   = Triisopropylsilane 
TLC   = Thin layer chromatography  
Tris-HCl  =  Tris(hydroxymethyl)aminomethane hydrochloride 
UV-Vis   = Ultraviolet visible spectroscopy 
V   = Valine 
 9 
WT   = Wild type 





































Proteins are amyloidogenic if they are able to misfold and subsequently self-assemble, 
resulting in highly ordered forms of the proteins known as amyloid fibrils. The name 
‘amyloid’ is derived from the Latin of starch, which arose from a reaction whereby iodine 
was used to stain brain tissue that had abnormal macroscopic appearances; the tissue 
stained blue on reaction with iodine and violet on addition of sulphuric acid, which was 
characteristic of starch. Later work, by Friedreich and Kekule in 1859, showed that amyloid 
actually did not contain carbohydrate as previously thought, due to its high nitrogen content, 
but was comprised of protein.  Amyloid has since been studied as a protein and 
subsequently identified as a class of proteins that are able to undergo structural changes, 
resulting in fibril formation.2 
 
1.2 Biological Importance 
 
Since the discovery of amyloid formation, it has been associated with many medical 
conditions and diseases. It is now thought there are approximately 50 conditions which are 
linked to misfolding proteins into amyloid fibrils, including Alzheimer’s disease, Huntington’s 
disease and Type II Diabetes. The diseases associated with amyloid fibrils are suspected 
to be caused either by aggregation of fibrils in the brain, resulting in neurodegenerative 
conditions, localised aggregation in a single tissue type or aggregation in multiple tissues.3  
 
For many years it was thought that the amyloid fibrils themselves were toxic and thus 
causing these conditions, but it has since been suggested that it is the smaller oligomers 
and small intermediate fibrils that are produced during the formation, shown in figure 1, that 
causes the toxic properties. This is a result of the loss of protein function once the fibril has 




Misfolded proteins are likely to be toxic as the unusual conformation will display some 
functional groups and hydrophobic surfaces that are usually contained within the folded 
protein. These groups could cause interactions that do not usually occur with other cell 
components, leading to cells malfunctioning. Smaller oligomers would also have a higher 
surface area, meaning more functional groups and side groups are exposed and free to 
interact, thus causing a higher toxicity relative to complete amyloid fibrils.6 The smaller 
oligomers formed in the process are also able to disrupt membranes, which can lead to 
disturbance of the transport of proteins and ion imbalances; a linear correlation has been 
reported between the level of Ca2+ across membranes when oligomers of the Ab42 protein 
bind to a cell membrane. This has resulted in cellular damage and ultimately could result in 
cellular death.7 Due to the instability and varying molecular weight and structure of toxic 
oligomers, their structure has not yet been determined in a high enough resolution to enable 
the molecular basis of the toxic properties to be resolved.  
 
Figure 1: A diagram showing the formation of amyloid protein fibrils.5  
(a) Misfolded protein monomers form protofibrils and mature fibrils (b) Misfolded monomers 
can also form off-pathway oligomers (c) Fragmentation of mature fibrils produces toxic 
fibrillar oligomers, before reforming mature fibrils (d) Oligomerisation and secondary 
nucleation of mature fibrils yields more toxic oligomers from the monomers 
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Although there are natural defences within cells that attempt to inhibit protein misfolding, 
these mechanisms can be overrun due to factors such as mutations within the cell, which 
could cause an increase in the rate of aggregation formation. The resulting accumulation of 
aggregates in affected tissues are predominant characteristics of these diseases; for 
example, extreme pain occurs in joints due to amyloid build up and memory impairment due 
to a build-up in the brain tissues.8  
 
This area of research has been of much interest recently, but there are still many 
fundamentals that are yet to be fully understood.  It is still unclear what causes the 
aggregation of amyloid to begin with and also the mechanism by which amyloid aggregates 
are recognised by other cells and their components.     
 
Clinical trials have been carried out on Alzheimer’s patients whereby drugs were used in 
order to stop amyloid formation. One issue to be faced is that drug companies need to 
determine that the aggregation of amyloid fibrils was reduced or stopped, whilst 
simultaneously the quality of life of the patients who took the drugs improved, particularly 
their memory and judgement. The testing of potential drugs for Alzheimer’s is also a slow 
process as Alzheimer’s is a progressive disease that causes the health and symptoms of a 
patient to deteriorate with time; the outcome of potential drugs that are started in the early 
onset of Alzheimer’s would take a while to show, if at all.9  
 
Semagacestat, shown in figure 2, is an example of one drug that has undergone clinical 
trials. The drug worked by inhibiting the enzyme that is responsible for the cleavage of 
amyloid precursor protein to pathogenic amyloid-b. However, the drug failed to show any 
cognitive improvement in patients treated with the drug compared to the placebo control 
and so the trial was stopped.10 Conversely, BAN2401 is a monoclonal antibody that is used 
to detect amyloid-b fibrils in the brains of Alzheimer sufferers. In over 800 patients treated 
with the antibody at five different doses, amyloid plaque levels were decreased compared 
to the control group. However, two separate trials of the cognitive function of these patients 
had contrasting results; one trial found a 30% reduction in slowing cognitive decline when 
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the highest dose of antibody was administered, whilst another trial failed to show a 
statistically significant difference between the patients and control group. Further work is 









These trials also highlight the issues faced with finding an effective therapeutic treatment. 
The most common explanation for trial failure is that the drugs are administered at the wrong 
time during the development of Alzheimer disease. It has been shown, by using positron 
emission tomography, that plaques form long before the symptoms of cognitive decline 
show and therefore amyloid-b levels may have plateaued by the time the drugs are being 
administered. Some trials are being carried out on patients who do not show any symptoms, 
whilst others are being carried out at different stages along the development of Alzheimer’s 
in order to establish the most critical point at which drugs should be administered for the 
most effective results.12  
 
1.3 Structure and Formation of Amyloid Fibrils 
 
Although proteins have a typical native folded structure, when in a solution they can adopt 
many different structures that have varying energy levels. Recent research has begun on 
intrinsically disordered proteins that favour an overall higher energy structure and also on 
proteins which can vary their structure depending on the specific conditions in which they 











Figure 2: The structure of Semagacestat11 
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The energy levels of proteins can be described by the ‘folding funnel’ energy landscape, 
shown in figure 3, which suggests that protein structures have different energy levels 
depending on a number of conditions13. Influences, such as solvent interactions, enthalpic 
contributions from non-covalent bonds and shielding of apolar protein surfaces14, are all 
factors in determining the free energy and entropy of the protein. It is only when the high 
entropy of unfolded proteins is overcome by these interactions that the typical native folded 
structure forms15. It is possible though that whilst forming this lower energy structure the 
protein can misfold, resulting in an unfolded or half-folded state, represented on the funnel 
landscape as a local minimum13. Fibrils are consequently formed when many proteins 
interact with each other in a regular, periodic arrangement; the interaction of ‘misfolded’ 
proteins leads to disease related amyloid, whilst intrinsically disordered proteins can also 
















The insoluble fibrils formed are straight, mainly unbranched structures that have a diameter 
between 6 - 12 nanometres and a length that ranges from a few nanometres to several 
micrometres, although this is variable depending on the protein monomer. The highly 
Figure 3: The folding funnel energy landscape of proteins13 
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ordered characteristic of amyloid originates from a core structure within the fibril that is 
composed of cross b-strands, a long extended chain of polypeptides. Hydrogen bonding 
between individual cross b-strands runs parallel to the fibril axis and creates a long b-sheet, 
which hydrogen bonds to other b-sheets to form the fibril core in protofilaments. The 
protofilaments are then able to twist around each other, forming fibrils.17 Figure 4 illustrates 














1.4 Mechanisms of Amyloid Growth 
 
Amyloid fibrils are generally considered to form by a nucleation growth mechanism.18 Either 
unfolded or partially folded protein monomers bind together in an ordered manner to form 
oligomers of varying structure and length. Oligomers can then further assemble to produce 
longer chains which form the precursors of amyloid fibrils, as shown in figure 5. During this 
process a high energy nucleus forms before polymerisation occurs rapidly.19 Although the 
conventional nucleation growth mechanism suggests that the growth should not increase 
exponentially, it is secondary processes, such as secondary nucleation and fibril 










Figure 4: The structure of fibrils 
(a) b-strand; (b) b-sheet; (c) protofilaments; (d) fibril core 
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after the nucleation phase is exponential and there is a lag time in which the individual 




During the assembly of the protein monomers, the monomer adopts a b-strand 
conformation; this is illustrated in figure 6.21 However, fibrils are able to fragment, producing 














Figure 5: The growth of amyloid fibrils20 
Figure 6: A side view of 3 ß-strands of GNNQQNY protein, arranged to form a ß-
sheet arrangement. GNNQQNY is a 7-residue section of the fibril-forming N-
terminus of the Sup35 protein21 
Left: The ß-strands viewed from the centre of the dry interface 
Right: The ß-strands viewed from the middle of the wet interface 
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Secondary nucleation can also occur during fibril growth. This is a process where oligomers 
form on the surface of a fibril that has already been created, potentially leading to an 
autocatalytic amplification of the process. It is thought this secondary nucleation leads to 
formation of toxic oligomers and so could provide an area of research for medical 
advances.23  
 
1.5 Analysis of Fibril Structure 
 
Amyloid fibrils are insoluble and thus there are limitations on the techniques that can be 
used in their analysis. Solution NMR does not yield any structure information, but more 
recently solid state NMR, has been used to further determine the atomic level structure.24  
 
X-ray fibre diffraction patterns of fibrils show the distances between the individual stacked 
b-strands and also between the b-sheets. The individual stacked b-strands are separated 
by a distance of approximately 0.47 nanometres, whilst the distance between the stacked 
b-sheets is between 0.6 and 1.1 nanometres25. Fibrils however are heterogeneous 
polymers, formed by the nucleated growth mechanism in which growth is rapid along one 
dimension; the cross-b strands resemble a one dimensional crystal, with a limited capability 
to produce a three dimensional lattice. Resultantly x-ray diffraction is limited in the 
information it provides as this technique cannot fully resolve their structure.26  
 
Circular dichroism determines the secondary structure of the protein monomer in the 
amyloid structure by using polarized light in the UV region. It can also be used to quantify 
the amount of a-helixes, b-sheets and random coils found within the protein structure. The 
cross-b sheet structure of fibrils allows certain dye molecules to bind. Congo red can be 
used under cross-polarised light, producing a green birefringence.27 Thioflavin T is a  
p-conjugated molecule that binds to the cross-b sheets; this changes the absorption and 
emission properties of the dye allowing the fibril structure to be analysed.  As fibrils grow by 
the nucleated growth mechanism, there is a lag phase that is observed before the growth 
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phase. This lag phase allows the growth of the fibrils to also be monitored as the dye only 











Cryo-electron microscopy has recently shown that the structure of amyloid fibrils is 
comparable to steric zippers, observed in peptide assemblies. Steric zippers are short 
peptides that consist of self-complementary b-sheets and as a result there are some 
differences between the structure of steric zippers and the amyloid fibril core. Amyloid is 
usually composed of twisted fibrils with packing defects, whilst steric zippers are untwisted 
b-sheets that are packed together densely.  Thus, the interactions within peptide 
microcrystals and amyloid fibrils are analogous.29  
 
1.6 Imaging Fibrils 
 
Transmission electron microscopy enables individual fibrils to be studied. Negatively 
stained species can be visualised in a dried state under high vacuum, allowing the 
framework of fibrils and growing fibrils to be examined. It enables features as small as  
1 – 2 nanometres to be seen, providing images of protein aggregates and fibrils and thus 






















Figure 7: The structure of the dye molecules used 
Left: Congo red dye 
Right: Thioflavin T dye 
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Atomic force microscopy allows the study of the structural information of the amyloid fibrils 
in three-dimensions, including the size, helicity, dispersity and uniformity of the fibrils. 
However, more advanced atomic force microscopy measurements allow the study of the 
biophysical properties of amyloid on the nanoscale, particularly on the mechanism of 
amyloid formation and on the characteristic of the protein aggregated. This is an advantage 
over both circular dichroism and infrared spectroscopy as these techniques are unable to 
determine the properties of single amyloid fibril. Conversely, without these techniques, it 
would not be known how the fibrils interact and the structures that they form could not be 
determined and thus, the combination of all techniques is favourable. Recent developments 
on atomic force microscopy methods have also revealed the mechanical properties on the 
nanoscale.31  
 
1.7 Amyloid as a Functional Material  
 
As a result of the continuous hydrogen bonding in the core, amyloid fibrils are very strong, 
with high thermal and chemical stability. They also exhibit good mechanical and 
electrochemical properties along with biocompatibility. This can prove advantageous in 












 Figure 8: Potential uses of amyloid fibrils
28 
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Self-assembled peptide nanomaterials, that contain the cross-b sheet core, have recently 
been used to build functional materials with a range of applications. Photosynthetic 
nanostructures have been made using self-assembling peptides with photosensitive and 
photo catalysts in order to produce light harvesting peptide hydrogels, which could help 
advance the research in solar energy.32  Cathode materials can also be made using certain 
self-assembling peptides as a template. The reaction produced carbon-coated FePO4 
nanotubes that worked as a cathode in lithium-ion batteries.33  
 
Perylene bisimides are able to self-assemble into photoconductive one-dimensional 
structures; these structures have random orientation of the bisimides, which restricts their 
use in conductive wires. However, research has shown that by using magnetic fields, the 
self-assembly can be controlled to produce aligned, directionally dependent thin films.  The 
strength of the magnetic field can be varied to change the degree of alignment; a stronger 
field results in more alignment whilst samples with a lower concentration of bisimides 
requires a weaker field for the same alignment effect to be produced. Studies showed that 
when the magnetic field was removed, the samples returned to their randomly orientated 
structures, but the alignment could be preserved if the sample was dried under the effect of 
the magnetic field. This highly ordered structure could potentially be used to create 
photoconductive films from an organic semi-conductor. However, it is not yet known the 
strength of magnetic field required in order to produce the directional dependence required 
within the films.34  
 
Self-assembling proteins can produce structures, with sizes ranging from the nanoscale to 
the macroscale. Self-assembling dipeptides can be modified to be incorporated into 
composite materials, forming supramolecular co-polymers. The resulting co-polymers have 
shown a potential to be used in nanostructures; they are able to form molecular motors with 
a metal-organic framework, deliver therapeutic agents and form piezoelectric-based 
sensors. Their potential in energy storage devices, with the energy storage of self-
assembled dipeptides as part of a larger structure, is one research topic that is currently of 
much interest. Vertically aligned peptide nanotubes were used to produce electrostatic 
 21 
ultracapacitors with a carbon nanotube structure. The peptide nanotube ultracapacitor 
showed a 30 times higher level of current response when compared to a standard carbon 
nanotube-coated electrode and other similar structures.35  
 
Amyloid have good electronic and optical properties, with some amyloid showing 
piezoelectric properties, allowing templates for biosensors and biochips to be produced. 
Nanotubes, made of self-assembled peptides, helped produced a composite electrode that 
had greater electrochemical activity; this could help improve the sensitivity of biosensors.36  
 
1.8 Biological Functions of Amyloid 
 
One benefit to healthcare could be in producing hard or soft tissue regenerative materials. 
Cell growth is influenced by the mechanical properties of its surroundings and so recent 
research has been undertaken to modify the solidity of a gel template using peptides in 
order to influence the type of cell produced. Hydrogels are an effective template for cell 
growth due to their network structure and ability to incorporate and interact with cells and 
bioactive material. The self-assembly of peptides has been utilised to produce a 
nanofibrous, bioactive hydrogel that acts as a three-dimensional scaffold for cells that need 
fixing to a support. The hydrogel is a rigid network containing ligands on its surface, 
mimicking an extracellular matrix for which the cells can grow.37 Peptide self-assembly 
offers structural flexibility and by using peptide amphiphiles as a template, the regeneration 
of bone and its growth can be stimulated. Similarly, a self-assembled peptide hydrogel 
scaffold was used to stimulate cartilage repair.38  
 
Despite the negative effects associated with the toxicity of amyloid, it is known that amyloid 
can provide many benefits both naturally and synthetically. One current area of research is 
the molecular level mechanism that distinguishes between toxic amyloid and beneficial 
amyloid. It is presently thought that bacteria ensure functional amyloid are produced by 
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controlling the nucleation step through a specific protein, eliminating uncontrolled 
polymerisation.39  
 
The stability and strength of amyloid fibrils, along with their high level of chemical and 
biological resistance, can provide an advantage for bacteria in their biofilms. Spherical 
Escherichia coli produced curli fibrils through a tightly controlled mechanism in which  
co-factors ensure the fibril production is not harmful in the intracellular environment. 
Comparable amyloid fibrils also constitute the biofilms of Salmonella and Bacillis subtilis.40 
Amyloid also aids the survival of Escherica coli strains, by protecting against bactericidal 
activity.  The stability of amyloid is also used by silk moths, who use an amyloid fold in 
eggshells; the eggshells contain chorion proteins which exist in predominantly amyloid form 
as it provides chemical separation and thus defence of the egg from the environment.41  
 
Epigenetics refers to an inheritable change in the gene expression of a cell, without 
alterations to the DNA sequences. Advances in the field of epigenetics have since been 
made to modify particular proteins and DNA due to external stimuli or the environment; this 
has resulted in changes to the characteristics displayed.42 A ‘switch’ in gene expression can 
be caused by a change in the usual environment of a cell due to a certain factor. Amyloid 
fibrils are able to bring about a change in a cell by being constituted of proteins that act as 
a particular class of amyloid fibrils, known as prions, in yeast. When the protein is soluble, 
as a non-amyloid, they are able to act as normal but when the proteins aggregate into 
amyloid, the specific function is ‘switched off’. This has been seen in Sup35P yeast proteins, 
which is a translation termination factor, causing the stop of protein synthesis. When 
Sup35P aggregates, the termination is ‘switched off’, which allows translation and protein 
synthesis to continue.43  
 
As a result, it is thought that more artificial materials could be produced using amyloid and 
their self-assembling mechanism, including underwater adhesives, artificial bones and 
organic photovoltaics.32 There is also potentially a more natural use of amyloid, such as that 
in nitrogen catabolism, functional coatings and hormone storage.44  
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1.9 Control of Amyloid Assembly 
 
Neurodegenerative diseases and other medical conditions all display amyloid aggregates 
in affected tissues. One study showed that amyloid formation uses an amyloid template in 
order to bind individual amyloid monomers. By creating a synthetic amyloid template with 
amyloid monomers attached to an activated surface, insulin monomers were able to deposit 
onto the template, forming fibrils. The fibrils formed at a much faster rate without a lag time 
and were found, by atomic force microscopy, to be longer and thinner than those usually 
produced in solution. Dyes were used to further study the fibrils formed, revealing that the 
amyloid formed by a structural change when the insulin monomers reacted with the 
template. As a result, this showed that a synthetic template can be used to control the 
assembly of insulin monomers.45  
 
The aggregation of amyloid monomers into fibrils is also thought to be influenced by 
environmental factors, such as metal ions and pH. This was investigated by using a 
synthetic template of b-amyloid monomers on an activated solid surface. Atomic force 
microscopy measurements showed that the addition of Cu2+ and Zn2+ ions resulted in the 
formation of amorphous aggregates but at an accelerated rate whereas Fe3+ caused 
amyloid fibrils to form at a neutral pH. However, when mildly acidic conditions were used 
none of the ions stimulated amyloid fibril formation.46  
 
Modification of the composition of peptides is another way that the self-assembly of the 
peptides can be altered. The C-terminus of D-tripeptide was marginally altered, which 
caused an increase in the self-assembling ability of the protein and an increase in the  
anti-cancer efficacy. This research could be used to increase the self-assembly formation 





1.10 Control of Assembly with DNA 
 
DNA can be folded in order to produce self-assembled intricate structures and shapes on 
the nanoscale. A single-stranded scaffold is produced for a desired shape, held in place by 
‘staple’ strands which self-assemble to the scaffold strands. The first shape to be produced 
from this technique was a one-dimensional barcode array48 before five helper strands and 
a long strand of DNA were combined in order to produce an octahedron.49 Since this, many 
advances have been made in the self-assembly of DNA, with more intricate shapes such 
as a smiley face and larger structures, including extended periodic lattices and a hexamer 




As DNA assembly is both powerful and precise, it can be used to control the positioning of 
other nanomaterials. Research has shown that semiconductor and metal nanocrystals can 
be controllably bonded to a scaffold double-stranded DNA template in order to produce 
nanostructures with optical properties.51  Gold nanospheres and nanocubes were used to 
alter the structure and fibrillation kinetics of fibrils. Due to the higher affinity of gold 
nanospheres with amyloid-b peptide, thus leading to stronger interactions of the 
Figure 9: AFM images of four different DNA origami shapes. The scale bars in 
the bottom row of images represent 100 nm. 
From left to right: star; disk with holes; triangle produced by rectangular domains; 
triangle comprised of trapezoidal regions with bridges between.50 
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nanospheres with the peptide, the increase in the rate of fibril formation was greater 
compared to gold nanocubes. As well as fibrils forming more rapidly with gold nanospheres 
than gold nanocubes, different morphologies were also seen in the fibrils formed. Gold 
nanocubes formed long mature fibrils that precipitated and intertwined with each other; in 
contrast, gold nanospheres formed fibrils that were shorter, wider and arranged themselves 
side-by-side.52 This contrast is clearly displayed in figure 10 below. 
 
 
Modified-DNA has been used in a confined template in order to mediate the assembly of 
these nanoparticles due to the sequence-specific binding of DNA. Research into the 
thermodynamic control of this assembly has enabled the templates to be specifically 
designed to yield nanoparticles on desired substrates with the correct size, shape and 
concentration. It is also thought that changes in temperature and time of the reaction will 
enable the growth of the substrate with nanoparticles to be most effective.53  
 
Following on from using modified-DNA as a template, nucleobase peptide amphiphiles, 
which are based on dipeptides, can exist as helical or curved substances in solution or as 
gels. The amphiphiles can self-assemble due to hydrophilic-hydrophobic interactions but 
can also interact with complementary nucleobases. This interaction allows the production 
of template structures with nucleobases that can be further varied due to their self-assembly 
formation.54 This provides proof-of-principle for control of amyloid formation through 
interaction with DNA. 
Figure 10: AFM images of: 
Left: Aggregates of Aβ(1−40) and gold nanospheres ∼20 nm in diameter after 72 hours 
incubation 
Right: Aggregates of Aβ(1−40) and gold nanocubes ∼20 nm in edge length after 72 
hours incubation52 
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More recently, DNA has been used as a template in order to control the assembly of 
individual colloidal nanoparticles. A template of specific nucleic acids and polymer pores 
were able to control the assembly of nanoparticles of varying shapes and sizes, resulting in 
conformations that can be controlled and thus changed. It also enabled controlled assembly 
on both the nanometre and micrometre scale. Consequently, the light interactions of optical 
materials that use nanoparticles can be controlled and further studied.55  
 
1.11 Control of Amyloid Assembly with DNA 
 
Research, by Gras’ and Seeman’s group in the USA, shows amyloid fibrils can be contained 
within DNA origami nanotubes. A DNA-peptide conjugate was annealed with a scaffold 
strand, which resulted in a DNA nanotube. The DNA region of the conjugate acted as a 
linker to form the nanotube, whilst the peptide was concealed inside the nanotube in order 
to nucleate the formation of amyloid fibrils. As a result, the amyloid fibrils were enclosed 
within the DNA nanotube, showing that the peptide successfully nucleated their formation 
and that a protein linked to a DNA molecule can be used to produce a bigger framework; 
this is shown below in figure 11.56 
Figure 11: Process of organizing amyloid fibrils using DNA origami56 
(a) The components required (b) A 20-helix DNA nanotube containing the peptide on the inside 
(yellow), and the sticky ends for attachment (blue) (c) The mixing of nanotubes with a peptide 
solution to form fibrils enclosed within the nanotubes. (d) The organised fibril on the platform.  
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A similar paper published showed that polymers were able to be templated using DNA 
bases. By using nucleobase-templated polymerisation with a DNA backbone of thymine 
with adenine monomers aligned complimentarily, a polymer was able to be synthesised of 
a similar weight and length to the template polymer used.57  
 
The bacteria Staphylococcus aureus is known to cause persistent infections by 
accumulating and thus producing a biofilm, which is produced through a matrix containing 
polysaccharides, extracellular DNA and proteins, including amyloid fibrils. It has been 
shown that the formation of amyloid fibrils is stimulated by the extracellular DNA, which 
causes the formation of specific phenol soluble modulins peptides; in conditions where the 
extracellular DNA was not produced, or contained mutations, a lack of amyloid was seen. 
Phenol soluble modulins were found to be less cytotoxic than the soluble peptide equivalent, 
showing that extracellular DNA may help to reduce the toxic peptides by favouring peptide 
aggregation, thus producing amyloid fibrils. Despite this, it is not yet known how all of the 
matrix components interact in order to contribute to the formation of the biofilm.58  
 
Other research has shown that certain peptide-DNA conjugates are able to controllably self-
assemble into amyloid-like fibrils. The fibrils form through a nucleation polymerisation 
process in which the driving force is the incompatibility of the hydrophobic peptides and 
hydrophilic DNA groups. p-p stacking and intermolecular interactions between the peptides 
and DNA groups leads to the formation of spherical structures, which act as nuclei for the 
nucleation step and thus can be combined into fibres with a b-sheet structure.59  
 
 
1.12 Project Aims 
 
The overall aim of this project is to use DNA base pairing interactions in order to modify and 
the assembly of Sup35, a protein that is known to form amyloid. A chemical linker will be 
synthesised in order to link the DNA strands with the protein and the growth of fibrils 
monitored to assess whether the growth can be reduced or controlled. The DNA will serve 
as a ‘template’ to control the length of the fibrils produced; this template is hoped to control 
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the amount of protein monomers that can form fibrils and also potentially lead to less 
fragmentation by strengthening the fibril. Less fragmentation could help to reduce the 
amount of the cytotoxic fragments formed and associated with neurodegenerative disease.  
 
Sup35 is an aggregate of eRF3, which is a yeast termination factor. The protein’s amino 
acid sequence is comprised of 685 residues and can be separated into three domains:  
N, C and M. The N domain contains a succession of a nine-residue oligomer, 
PQGGYQQYN, with a total of 123 residues that are responsible for amyloid formation. 
There is a high quantity of polar residues in this domain, such as glutamine (Q), which is a 
common characteristic of amyloid-forming proteins.60 Polar functional groups are also found 
in residues 124 to 245, the M domain, whilst the remaining residues, 246 to 683, form the 
C domain and are used in the termination activity of the protein.61 As this project will not be 
utilising the protein’s termination activity, the smaller Sup35NM protein is to be used. Some 
modifications have been carried out, with a histidine tag added to the N domain and an 
additional short, flexible linker in the C domain; the flexible linker consists of serine (S) and 
glycine (G) in the arrangement of GSGGSGGSGC. An additional cysteine is also added in 
order to ensure the correct interactions take place, resulting in the Sup35NM LCys protein.62 
This protein will be synthesised by Liisa Lutter, who works in the Xue lab in the Kent Fungal 
Group. 
 
In order to link the protein with a DNA strand, maleimide chemical linkers will be 
synthesised, as shown in figure 12. This will covalently attach to the Sup35NM LCys protein, 
whilst also hydrogen bond to a single base of DNA, as drawn in figure 13. By creating a 
DNA backbone, the self-assembly of amyloid fibrils can be controlled. Fibril growth could 
be controlled using different length DNA backbones or different DNA sequences and the 
effect of DNA upon the assembly of Sup35NM LCys proteins studied. A 1:1:1 ratio of 
protein, chemical linker and DNA monomer will be used to begin with, but this will be varied 
in order to see whether the protein monomers still bind to the DNA backbone if not all of 














A second chemical linker, a maleimide phosphoramidite, will also be made in this project; 
the structures are shown in figure 14. This linker will be covalently bonded to a strand of 
DNA and also to the Sup35NM LCys protein. When the proteins assemble to form amyloid, 
one of the fibrils will be attached to the DNA strand; this DNA strand will be able to crosslink 
with a complementary DNA strand attached to another amyloid, as displayed in figure 15. 
The level of crosslinking can then be controlled by altering the number of fibrils in the 





Figure 13:  
Left: A cartoon diagram showing the cross-linking of two amyloid (purple) by complementary 
DNA strands (blue) covalently bonded to a phosphoramidite maleimide linker (grey) 

















Figure 12: The two maleimide chemical linkers 
Left: Compound 4 























Left: A cartoon showing the controlled assembly of peptides (purple) by using a chemical 
linker (grey) and a DNA backbone (blue) 





























Figure 14: The two maleimide phosphoramidite chemical linkers 
Left: Compound 7, with the maleimide ring 
Right: Compound 10, which incorporates the phosphoramidite group and furan ring 
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Amyloid can broadly be defined as a protein that consists of polypeptide chains, generally 
with a β-sheet structure, that can aggregate into long fibres. This research focuses on 
synthesising a chemical linker whereby one end is able to covalently attach to the chosen 
protein, Sup35NM LCys, whilst the end hydrogen bonds to a strand of DNA, in order to 
prevent the self-assembly of the protein into amyloid fibrils.  
 
The linkers, as shown again in figure 16, have two different functional groups. One end 
contains a maleimide ring, which is required to covalently attach to the sulphur containing 
linker cysteine on the protein; the double bond of the maleimide ring readily reacts with the 
thiol group of cysteine to form a stable carbon-sulphur bond. The opposite end of the linker 
contains three nitrogen groups, which are used to facilitate the hydrogen bonding with a 
base on the chosen DNA strand. Previous research has shown that thymine can be bonded 
to 2,6-Diaminopurine (DAP), a similar compound to adenine, by hydrogen bonding; as a 
consequence, the double helix formed predominantly had increased stability.63 Two slightly 
different chemical linkers will be synthesised, with the length of the carbon chain between 


























Figure 16: The two maleimide chemical linkers 
Left: Compound 4 
Right: Compound 5 
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The protein selected to be used is Sup35, a yeast termination factor, although a slightly 
modified version will be used.  The smaller Sup35NM protein will be used, as the C domain 
is not used in the [PSI+] phenotype and only in the termination activity of the protein and 
hence not required. A linker cysteine group, LCys, will also be added resulting in the protein 
Sup35NM LCys.  
 
Once conjugated, the DNA-linker-protein system, as shown in figure 17, will be studied to 
determine if the fibril growth can be controlled using the DNA backbone. Variations of DNA 













2.2 General Considerations 
 
All solvents, regents and buffer components were purchased from Fisher or Sigma Aldrich, 
except those listed below.  
 
NMR spectra were obtained on a Bruker AV2 400 MHz spectrometer; the spectra were 
calibrated to the centre of the set solvent peak and chemical shifts then reported in parts 
per million (ppm). Spectra were analysed using ACD labs.  
Figure 17: The DNA-Linker-Protein conjugate using the N-(6-Acetamidopyridin-2-
yl)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)Hexanamide linker 
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UV-Vis Spectroscopy data was collected by a Nanodrop spectrophotometer. The pedestal 
was cleaned with ethanol and deionised water before a black was run of deionised water  
(2 µL). The sample was then loaded (2 µL), a spectrum run in the wavelength of  
220 – 350 nm and the process repeated 3 times. In order to determine the DNA 
concentration, the measured A260 value was multiplied by the A260 value calculated from 
the IDT Oligoanalyser tool64.  
 
MS data was attained by using one of two methods. For small organic molecules, a Thermo 
MSQ Plus LC-MS system was used. However, for larger samples, or those containing 
protein, peptide or DNA, a Bruker micrOTOF-Q Mass Spectrometer was used. 
 
DNA strands were purchased from Integrated DNA Technologies or synthesised using an 
Expedite 8909 System (Biolytic). Phosphoramidite reagents (dA-CE, dT-CE, dG-CE, and 
dC-CE), cap A, cap B, deblock and oxidiser were purchased from Link Technologies; the 
phosphoramidite reagents were diluted as recommended using dry acetonitrile. The DNA 
strands were synthesised on a 1 µM scale. 
 
SDS-polyacrylamide gel electrophoresis (12 %) was also carried out.  The gel was run for 
60 minutes at 75 - 80 Volts, depending on the stack, before the voltage was increased and 
the gel run for a further 120 minutes.  
 
Liisa Lutter from the School of Biosciences at the University of Kent expressed and purified 
the protein to be used. Elution G buffer was composed of 20 mM Tris-HCl, 0.5 M NaCl and 























A solution of acetic anhydride (5.80 g, 0.057 mol, 1 mol equiv) in dry THF (15 mL) was 
added dropwise, over 2 hours, to a stirring solution of 2,6-diaminopyridine (7.52 g,  
0.069 mol, 1.2 mol equiv) and triethylamine (8.33 g, 0.082 mol, 1.4 mol equiv) in dry THF 
(85 mL). Once added, the reaction solution was left to stir overnight. Water (40 mL) was 
then added and the solvent removed by rotary evaporation before the solution was left to 
recrystallise overnight. The solution was dried under vacuum in a Büchner funnel and 
washed with ice water and diethyl ether, producing dark green crystals (6.15 g,  
0.0406 mol, 72 % yield). 
 
1H NMR (400 MHz, DMSO), ppm: 9.88 (1H, s, NH), 7.32 (1H, t, J = 7.9 Hz, ArH),  
  7.21 (1H, d, J = 7.7 Hz, ArH), 6.16 (1H, dd, J = 0.8 Hz, 8.0 Hz, ArH),  
  5.78 (2H, s, NH2), 2.02 (3H, s, CH3), 
13C NMR (400 MHz, DMSO), ppm: 168.87, 158.83, 150.60, 138.91, 103.30, 100.79, 24.04 
MS (ESI, positive mode): calculated [MW]H+ = 152.1, m/z found = 152.0 
 
 
Scheme 1: Acetylation of 2-6-diaminopyridine 
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Tert-Butyl(2-((6-Acetamidopyridin-2-yl)Amino-2- Oxoethyl)Carbamate (2) 
 
 
Compound 1 (3.71 g, 0.025 mol, 1 mol equiv) was added to DCM (100 mL) and stirred until 
dissolved. N-Boc Gly (4.49 g, 0.026 mol, 1 mol equiv), EDC-HCl (5.27 g, 0.028 mol,  
1.1 mol equiv) and DMAP (a few grains) were added and the solution stirred overnight. The 
reaction solution was washed three times with 2M sodium hydroxide, once with water and 
then finally with brine. Magnesium sulphate was used to dry the organic layer before being 
filtered out. The solvent was removed by rotary evaporation, yielding a cream/light brown 
solid (3.66 g, 0.0118 mol, 48 % yield).  
 
1H NMR (400 MHz, CDCl3), ppm: 8.32 (1H, s, NH), 7.97 (1H, s, ArH),  
  7.80 (1H, d, J = 7.6 Hz, ArH), 7.60 (1H, t, J = 8.1 Hz, ArH), 3.92 (2H, s, CH2),  
  2.13 (3H, s, CH3), 1.40 (9H, s, C(CH3)3) 
13C NMR (400 MHz, CDCl3), ppm: 168.79, 168.25, 149.70, 148.86, 140.76, 109.83, 45.03,  
  28.33, 24.68 



















Compound 2 (0.90 g, 2.920 mmol) was dissolved in TFA (3.43 mL). TIPS (0.15 mL) and 
water (0.15 mL) were added and the solution stirred for 1 hour. Diethyl ether (47.00 mL) 
was then added and the solution stirred overnight. Overnight a precipitate had formed. The 
solution was centrifuged, the supernatant removed and diethyl ether added; this process 
was repeated three times. The product was dried under vacuum in a Büchner funnel and 
collected as a white solid (0.902 g, 4.33 mmol, 148 % apparent yield). 
 
1H NMR (400 MHz, DMSO), ppm: 10.56 (1H, s, NH), 10.12 (1H, s, NH), 8.13 (3H, s, NH2),  
  7.78 (3H, t, J = 6.7 Hz, ArH), 3.37 (2H, s, CH2), 2.12 (3H, s, CH3) 
13C NMR (400 MHz, DMSO), ppm: 169.84, 158.42, 149.84, 140.81, 115.27, 109.24, 24.51 
MS (ESI, positive mode): calculated [MW]H+ = 209.1, m/z found = 209.2, 231.2 (Na+  










Compound 3 (0.26 g, 7.948 x 10-4 mol, 1 mol equiv) was dissolved in acetic acid (8 mL) and 
maleic anhydride (0.09 g, 8.970 x 10-4 mol, 1.1 mol equiv) was added. The solution was 
Scheme 3: Deprotection of compound 2 
Scheme 4: Addition of maleic anhydride to compound 3 
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heated to 180 °C and refluxed overnight. The solvent was removed by rotary evaporation 







HATU (0.96 g, 2.522 mmol, 1.1 mol equiv) and 6-maleimidohexanoic acid (0.54 g,  
2.533 mmol, 1.1 mol equiv) were dissolved in a solution of triethylamine (0.35 mL,  
1.1 mol equiv) and DCM (10.0 mL). The solution was stirred for 30 minutes, before  
2,6-diaminopyridine (0.25 g, 2.300 mmol, 1 mol equiv) was added. The solution was left to 
stir overnight. The solution was washed with water, the organic layer dried with magnesium 
sulphate and the solvent removed by rotary evaporation, yielding the product as a light 
brown residue (0.59 g, 1.942 mmol, 84 % yield).  
 
1H NMR (400 MHz, CDCl3), ppm: 9.01 (1H, s, NH), 7.77 (2H, d, J = 7.9 Hz, ArH),  
  7.64 (1H, t, J = 8.0 Hz, ArH), 7.45 (2H, d, J = 8.2 Hz, ArH), 6.62 (2H, s, CH),  
  3.44 (2H, t, J = 6.2 Hz, CH2), 2.31 (2H, t, J = 8.0 Hz,  CH2), 2.13 (2H, s, NH2),  
  1.64 (2H, m, J = 7.9 Hz, CH2), 1.54 (2H, m, J = 7.6 Hz, CH2),  
  1.30 (2H, m, J = 7.5 Hz, CH2) 
13C NMR (400 MHz, CDCl3), ppm: 176.86, 175.79, 159.64, 157.53, 140.90, 134.88,  
  105.94, 41.54, 36.98, 29.89, 22.32, 18.52 
 





HATU (1.01 g, 2.649 mmol, 2 mol equiv) and 6-maleimidohexanoic acid (0.56 g,  
2.656 mmol, 2 mol equiv) were dissolved in a solution of triethylamine (0.37 mL,  
2 mol equiv) and DCM (15 mL). The solution was stirred for 90 minutes, before compound 
1 (0.25 g, 1.323 mmol, 1 mol equiv) was added and stirring continued overnight. The 
solution was washed with saturated potassium carbonate and brine, the organic layer dried 
with magnesium sulphate and the solvent removed by rotary evaporation, yielding the 
product as an orange oil (Crude product: 0.356 g, 1.034 mmol, 62 % yield). The product 
was purified by column chromatography, using a running solvent of 3 % methanol in DCM. 
The desired fractions were combined and the solvent removed by rotary evaporation. 
(Purified product: 0.015 g, 4.4 x 10-5 mol, 3 % yield). 
 
1H NMR (400 MHz, CDCl3), ppm: 7.83 (5H, m, J = 7.7 Hz, 8.0 Hz, ArH and NH),  
  6.64 (2H, s, CH), 3.47 (2H, t, J = 7.2 Hz, CH2), 2.32 (2H, t, J = 7.5 Hz, CH2),  
  2.16 (2H, s, CH3), 1.69 (2H, m, J = 7.6 Hz, CH2), 1.56 (2H, m, J = 7.5 Hz, CH2),  
  1.31 (2H, m, J = 7.7 Hz, CH2) 
13C NMR (400 MHz, CDCl3), ppm: 176.30, 169.90, 147.87, 140.56, 133.00, 108.23, 37.90,  
  36.50, 27.80, 26.03, 23.53, 23.50 






Scheme 6: Addition of 6-maleimidohexanoic acid to compound 1 
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2.3.2 Conjugation of Linker and Protein 
 
Sup35NM LCys in guanidine was thawed, DTT (0.1 mL) added and left for 1 hour. LCys in 
guanidine was then loaded into a PD10 column and eluted to a volume of 3.5 mL using 
Elution G buffer. The absorbance of the protein was measured and the concentration 
calculated to be 11.5 µM in 3.5 mL. 
Linker 1B (0.5 mg, 1.453 mmol) was dissolved in methanol (1 mL).  
 
8 samples were then prepared using the protein and linker solutions, with 2, 5, 10 or 20 
equivalents of linker to protein, in the following quantities; 
 
2 equivalents of linker to protein:      0.39 µL linker, 24.6 µL protein  
5 equivalents of linker to protein:      0.97 µL linker, 24.03 µL protein  
10 equivalents of linker to protein:    1.94 µL linker, 23.06 µL protein  
20 equivalents of linker to protein:    3.88 µL linker, 21.12µL protein  
  
4 of the samples, one of each of the different equivalents, were reacted overnight at room 
temperature, whilst the remaining 4 were conjugated overnight at 37 °C.  The samples 












2.4 Results and Discussion 
 







Compounds 1 – 4 were synthesised using a method from literature, that was adapted in 
order to produce the target molecule. The first reaction was an acetylation reaction for which 
the method used was taken directly from the paper.65 All three attempts of this reaction have 
been carried out using the same protocol, as described above, with the products being 
successfully made with good yields. The literature procedure reported a yield of 47.3% and 
the reactions carried out produced yields between 55 % - 60 %; the slightly higher yield is 
most likely due to a by-product, in which there is the addition of the acetyl group onto both 
nitrogen atoms in the starting regent (2,6-diaminopyridine). The 1H and 13C NMR spectra 
produced are also very comparable to that in the literature, indicating the synthesis had 








This reaction was an amide coupling reaction of compound 1 with N-boc glycine, using 
EDC.HCl as the coupling regent and DMAP as a catalyst, as widely published in literature.66 
The reaction worked well on both attempts, with the target product being synthesised. 
Despite this, on the second attempt of the reaction a black precipitate formed overnight; it 
is likely that the precipitate was undissolved starting reactant, N-(6-aminopyridin-2-
yl)acetamide, as the reaction resulted in a lower yield compared to the previous attempt. 
The precipitate was removed by vacuum filtration on a Büchner funnel before the work-up 
was carried out as normal. The 1H NMR spectra obtained for both of the reaction attempts, 














Reaction 3 of the synthesis was the deprotection of tert-butyl-(2-((6-acetamidopyridin-2-
yl)amino-2-oxoethyl)carbamate, which used TFA, TIPS and water. Deprotection reactions 
using TFA are common, whilst these particular reaction conditions are often used in the 
cleavage of peptides from the resin during synthesis.67 All four attempts of this reaction 
have been successful, producing the desired product with good yields, although residue 
solvent has often remained. The main difference between these reactions attempts has 
Figure 19: 1H NMR of the amide coupling of N-(6-aminopyridin-2-yl)acetamide 
(compound 2) 
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been the work-up method. Two of the attempts produced a fine precipitate that, when 
filtered on a Büchner funnel, flowed through and was not filtered out. As a result, the solution 
was centrifuged 3 times; the supernatant was removed and diethyl ether added after each 
spin before the solid was filtered out and dried. On the other two attempts of the reaction, a 
more crystalline and ‘sticky’ precipitate formed, which could be filtered out of the solution 





The addition reaction of acid anhydrides to amines in order to synthesise amides are 
frequently undertaken.68 However, this reaction has proved problematic and so the reaction 
conditions have been changed multiple times to try and obtain a successful product. Initially 
the protocol was adapted from literature but was adjusted to suit the desired target 
molecule.69 As the preliminary reaction did not work, shown by the 1H NMR spectrum, the 
first adjustment made was to decrease the reaction time from ~72 hours to just ~24 hours, 
in case the reaction equilibrium was favouring the reverse reaction, thus causing the 
maleimide ring to open.  
 
Figure 20: 1H NMR of the deprotection of  tBu(2-((6-acetamidopyridin-2-yl)amino-2-
oxoethyl)carbamate (compound 3) 
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Another change was made to the work-up; water was originally added to the reaction before 
washing with ethyl acetate, sodium hydroxide and brine. However, this was changed so 
instead, excess dichloromethane was added to increase the volume of the reaction solution 
to aid separation and the solution was then washed with hydrochloric acid, potassium 
carbonate and brine.  
 
The final change made was to the ratio of the reagents and the reaction temperature. A 
large excess of maleic anhydride was originally used, but this was reduced to a 1 : 1.1 ratio 
of amide to anhydride. Alongside this reaction, the synthesis of maleimide alcohol was being 
carried out for the synthesis of the phosphoramidite maleimide linker; during this, the 
reaction temperature was increased to 180 °C as this increased the yield and so the reaction 
temperature of this reaction was likewise increased.  
 
The 1H NMR spectrum and MS data of the latest reaction attempt of the reaction showed 
that the desired product was not synthesised. The desired product would have an expected 
MW of 288.1 g mol-1; ESI positive conditions were used and so the target peak should 
appear around 289.1 g mol-1. However, in the MS spectrum obtained for the synthesised 












Figure 21: 1H NMR of the addition of maleic anhydride to N-(6-acetamidopyridin-2-yl)-2-















As the addition of maleic anhydride to N-(6-acetamidopyridin-2-yl)-2-aminoacetamide was 
proving unsuccessful and linker 1A was thus not being synthesized, a new method was 
devised which would yield a similar product, although with the longer alkyl chain.  
 
This reaction was run as an experimental reaction to see if a new protocol, using HATU to 
generate an activated ester, would successfully yield the product. 2,6-Diaminopyridine was 
used as it is more nucleophilic than the N-(6-aminopyridin-2-yl)acetamide and so would 
hopefully produce the desired product. 
 
The 1H NMR spectrum, shown in figure 23, indicated that although only a crude product 
had been produced, as the solution contained some starting materials, the desired product 
had been formed.  As a result, the same protocol was used for the addition of  
6-maleimidohexanoic acid to N-(6-aminopyridin-2-yl)acetamide (compound 1) with the 
addition of a purification step. Despite 2,6-diaminopyridine being more nucleophilic than  
N-(6-aminopyridin-2-yl)acetamide used in the next reaction, the acetamide would be better 
to use as the starting reagent as one of the nitrogen atoms  is already acetylated. The 
Figure 22: The mass spec data of the addition of maleic anhydride to N-(6-
acetamidopyridin-2-yl)-2-aminoacetamide (compound 4)  
 45 
addition of 6-maleimidohexanoic acid to 2,6-diaminopyridine could lead to multiple side 





The first attempt of this reaction followed the same protocol as for the amide coupling of  
N-(6-aminopyridin-2-yl)acetamide and thus used EDC-HCl and DMAP in order to react the 
two reagents. This was unsuccessful as the reaction solution was swamped with DMAP, 
and so the reaction was repeated without the catalyst, but with no success, most probably 
due to the lack of catalyst. The next two attempts at the reaction used DCM as the solvent, 
but with varying ratios of the starting materials; 1 : 2 : 2 equivalents of amine :  
6-maleimidohexanoic acid : EDC-HCl was then increased to 1 : 3 : 2. However, during the 
work-up of the reaction it was noted that not all the starting amine was dissolving in the 
solvent. Thus, the NMR spectra produced was mainly just the starting reagents, with traces 
of the desired product in very little quantity; little presence of the aromatic protons between 
7 – 8 ppm expected in the product was seen in the spectra. The starting amine was also 
dissolved in THF but this also yielded no success.  
 
HATU and triethylamine were used to form a HOAt ester, which was then reacted with the 
amine (compound 1). The NMR spectrum of the first attempt did not show the expected 
Figure 23: 1H NMR of the addition of 6-maleimidohexanoic acid to 2,6-diaminopyridine 
(compound 5) 
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peaks and so the ratios of the reagents were changed. The ratio of acetamide :   
6-maleimidohexanoic acid : triethylamine : HATU was changed from 1 : 1.1 : 10 : 1.1 to  





This compound has an expected molecular weight of 344.15 g mol-1, which can be seen in 
the MS data obtained. The negative ion mode shows the main peak at 343.14 g mol-1 
([MW]H-) with an additional peak at 301.13 g mol-1, which is due to the dissociation of the 
acetyl group. In the positive ion mode, there is the expected peak at 345.16 g mol-1 ([MW]H+) 
but also a peak at 666.45 g mol-1; this was shown to result from a contaminant in the HPLC 
system used to inject the sample when a blank run was undertaken. Therefore, the NMR 








Figure 24: 1H NMR of the addition of 6-maleimidohexanoic acid to N-(6-aminopyridin-2-





















2.4.2 Conjugation of Linker and Protein 
 
The protein has a MW of 31,260 Da, which combined with the MW of the linker at 344 Da, 
would produce a conjugate with a MW of 31,604 Da. The samples with 2 and 5 equivalents 
of linker to protein showed no peak for the conjugate, whereas the samples containing 10 
and 20 equivalents of linker to protein displayed a peak in the region of the MW of the 
conjugate at both room temperature and 37 °C. One sample for  each temperature showed 
a difference of 15 Da, whilst another sample showed a difference of 13 Da.  However, the 
MS data obtained showed that the samples conjugated at room temperature, displayed in 
figure 26, did not work as successfully as those left at 37 °C, shown in figure 27, as less 
conjugate was produced. 
Figure 25: The mass spec data of the addition of 6-maleimidohexanoic acid to N-(6-
aminopyridin-2-yl)acetamide (compound 6) 
Above: Negative ion mode 





























Figure 26: MALDI-TOF MS data of the conjugates incubated at room temperature 










































Figure 27: MALDI-TOF MS data of the conjugates incubated at 37°C. 




Overall, the synthesis of linker 1A, the structure of which is shown in figure 28, was 
unsuccessful. The first three reactions in the synthesis of N-(6-acetamidopyridin-2-yl)-2-
(2,5-dioxo-2,5-dihyrdo-1H-pyrrol-1-yl)acetamide were carried out with positive results. 
However, the final reaction of the addition of maleic anhydride continuously proved 










Nevertheless, linker 1B, also shown in figure 28, was synthesised with more desirable 
outcomes.  The target molecule, N-(6-acetamidopyridin-2-yl)-2-(2,5-dioxo-2,5-dihyrdo-1H-
pyrrol-1-yl)hexanaimde, was synthesised. The structure was confirmed by 1H and 13C NMR 
spectra and MS data. As a result, the conjugation with the protein was also carried out, 
which also yielded encouraging results, due to MS data confirmed that the conjugates had 


























Figure 28: The two maleimide chemical linkers 
Left: Compound 4, which is linker 1A 
Right: Compound 5, which is linker 1B 
 
 51 




Peptides are molecules comprised of more than two amino acids, bonded through covalent 
peptide bonds between the carboxyl group of one amino acid and the amino group of the 
sequential amino acid. Some soluble peptide chains are able to self-assemble into insoluble 
fibrils, known as amyloid fibrils. The self-assembly causes the peptide to become resistance 
to degradation and thus is often associated with disease and neurodegenerative 
conditions.70 From recent research has emerged the Waltz algorithm, which considers both 
the specific residue type and position of peptides in order to determine if the peptide 
contains any amyloidogenic regions and thus be able to form self-assembled fibrils.  Three 
peptides which have been recognised as being able to form highly ordered amyloid fibrils 
have the structures of HYFNIF, RVFNIM and VIYKI.71  
 
The main objective of this research was to conjugate a Waltz peptide with linker 1B, a 
maleimide chemical linker, previously synthesised in chapter 2; this could potentially allow 
DNA-templated amyloid as shown formerly in figure 13.  The Waltz peptide, synthesised by 
Akiko Sato in the Serpell group, is comprised of 8 different amino acids with an acetyl group 
at one terminus and an amide group at the other; this gives the general structure of  
Ac-CGSGHYFNIF-NH2 , as shown in figure 29. Conjugation of the peptide and linker arises 
through thiol-maleimide chemistry, whereby the maleimide ring opens and reacts with the 
sulphur containing thiol group, present in the side chain of cysteine.   
 




Two solutions (160 µL) were prepared, consisting of peptide (80 µL, 100 µM) and linker  
(80 µL, 200 µM). TCEP (4 mM) was also added to one of the solutions. TLC plates were 
run and MALDI-TOF MS data obtained.  
 
3.3 Results and Discussion 
 
 
A preliminary run of the conjugation was carried out, in which the linker and peptide 
solutions were combined in a 1:1 ratio (80 µL, 200 µM). The sample was heated at 37°C 
overnight, but analysis by TLC showed that the conjugation had not worked as no new 
bands could be seen. For the first attempt, the linker was dissolved in methanol, but the 
peptide solution was prepared in water. Waltz peptides form aggregates very quickly in 
water and so it was likely that the peptide had aggregate within itself, before being able to 
react with the linker.  
 
As a result, the solvent system was changed to an organic solvent. The linker was again 
dissolved in methanol, but the peptide was prepared in a solution consisting of 1:3 parts 
HFIP and methanol; the presence of HFIP aids the solubility of the peptide, which is 
otherwise usually insoluble in methanol. Three samples were formed, each with the same 
amount of linker (200 µM), but with excess peptide (200 µM, 400µM, 1000 µM respectively). 
TLC analysis showed the presence of new bands on the plate, which MALDI-TOF MS data 
confirmed to be the conjugates; the MW of the linker is 344.15 g mol-1, the peptide has a 
MW of 1184.56 g mol-1, which resulted in an expected MW of the conjugates at  








Figure 30: MALDI-TOF MS data of 1:1 equivalent of peptide to linker 
[MW]H+ 




From this, the conjugation was repeated, using the same solvent system before because it 
was shown to work. However, instead of using excess peptide, an excess of linker was 
used, as it is easier and more economical to produce.  Two solutions (160 µL) were 
produced, with peptide (80 µL, 100 µM) and linker (80 µL, 200 µM); TCEP (4 mM) was also 
added to one of the solutions in order to reduce the disulphide bond. TLC plates were run 
again, which positively showed the appearance of new, potential conjugate bands. MS data 
for this sample displayed a peak in the region expected for a conjugate, shown below in 
figure 33; however, instead of the peak occurring at 1529.71 g mol-1, which would represent 
[MW]H+, the peak occurred at 1530.64 g mol-1 which corresponds to [MW]2H+. 







[MW] + 23 
Na+ adduct 















In order to further analyse the conjugates, the reaction was scaled up using a mixture of the 
conditions used before. An organic solvent system remained, but without the presence of 
TCEP, and an excess of peptide was used as the purification of the conjugate solution 
would be easier. Three samples (160 µL) were prepared of the linker at a higher 
concentration (80 µL, 400 µM), combined with the peptide at 1 equivalent (80 µL, 400 µM) 
and at 2 equivalents (80 µL, 800 µM). After heating in the thermocycler, the TLC plates 




On the whole, the conjugation of the Waltz peptide with linker 1B, N-6-acetamidopyridin-
yl-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide, has produced positive results. 
Once the optimal conditions for the conjugation had been found, the reactions have been 
successful, with TLC and MS data confirming the expected conjugates had been made.  
Although further examination of the conjugates could not be carried out, it is known the 
conditions for which the conjugation works best and so there is potential for this work to 
provide interesting results in the future.  
[MW] 2H+ 
 
Figure 33: MALDI-TOF MS data of 1:2 equivalents of peptide to linker 
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This chapter of research focuses on synthesising two slightly different chemical linkers. The 
objective of these linkers is to provide a molecule that covalently connects a strand of DNA 
with a cysteine group of an amyloid-forming protein, Sup35NM LCys. When the protein 
forms amyloid fibrils, the DNA strand of one fibril will be able to crosslink with a DNA strand 
attached to another fibril by complementary hydrogen bonding. The level of crosslinking 
could potentially then be regulated by varying the amount of DNA strands bonded to the 
protein through the chemical linker.  
 
The first linker, as shown on the left in figure 34, used a solution phase strategy to conjugate 
the linker to the DNA strand; it also contains a maleimide ring in order to covalently bond 
the linker with the protein through thiol-maleimide chemistry. The second linker, as shown 
on the right in figure 34, has a phosphoramidite group which allows the linker to be 
covalently bonded to the desired DNA strands by solid phase synthesis. The linker also 




























Figure 34: The two chemical linkers 
Left: Linker 2A (compound 7) with the maleimide ring 
Right: Linker 2B (compound 10) which incorporates the phosphoramidite group 
and furan ring 
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Sup35NM LCys continued to be the chosen protein for the conjugation reactions, 
synthesised by the Kent Fungal Group in the School of Biosciences. Once conjugated with 
the protein and DNA, the protein-linker-DNA conjugate will be able to assemble into 
amyloid. Two complementary DNA strands will be used so when assembled, the DNA 
strands will be able to crosslink to each other, allowing the templation of amyloid fibrils.  
Once achieved, the level of crosslinking can be varied by differing the number of fibrils in 
the amyloid that are covalently bonded to the linker and thus a DNA strand.  
 
A similar technique has been used to create peptide-DNA conjugates that reversibly self-
assemble into intertwined fibrils and bigger structures with fibrillar networks. Peptide-DNA 
structures were produced from nanofibers, formed from alkylated peptides, covalently 
bonded to an oligonucleotide. A peptide-DNA motif, with the complementary DNA 
sequence, was then reacted with this structure, which lead to the DNA strands cross-linking. 
This led to a hydrogel being created, whose formation could be reversed and broken down 
into the single-stranded DNA-peptide components; this was achieved either by the addition 






































Figure 35: The DNA-Linker-Protein conjugate 
Above:  With compound 7 as the linker 




4.2.1 Synthesis of DNA 
 
The DNA strands were synthesised on an Expedite 8909 DNA synthesiser by 
phosphoramidite chemistry that have been used previously in literature and within the 




Two complementary DNA strands, with a spacer of 5 thymine bases, were made on the 
synthesiser. The strands required were, 
 
DNA 1: TT TTT GTC AAC GGT TAT GTC  
 DNA 2: TT TTT GAC ATA CCA GTT GAC 
 
A 5 base thymine spacer was used to add flexibility to the DNA strands as it is not involved 
in hybridisation. It eventually would increase the space between the DNA and protein, 
leading to less interference in the self-assembly of the DNA-linker-protein strands. These 
Figure 36: The synthesis of DNA by the phosphoramidite method 
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DNA strands were used as they are complementary to each other, but do not self-dimerise, 
form any secondary structures, such as hairpins or loops, and show no secondary folding.  
DNA 1 has a melting temperature of 48.8 ºC, whilst DNA 2 has a melting temperature of 
48.2 ºC.  
 
A gas leak test was carried out on the synthesiser and the lines were primed with the 
reagents before the desired sequence and settings were entered onto the programme. The 
column, containing the glass beads onto which the DNA was to be made, was placed into 
the synthesiser and the sequence started. The synthesis was monitored by measuring the 
optic absorption of the trityl cation at each detritylation step. 
 
Once completed, the columns were removed from the synthesiser and placed in the freezer 
until needed. 
 
4.2.2 Synthesis of Linkers  
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester Linker 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester (7) 
 
 
Anhydrous DCM (100 mL) was added to a flask containing 6-maleimidohexanoic acid  
(0.45 g, 2.017 mmol, 1 mol equiv), N-hydroxysuccinimide (0.70 g, 6.108 mmol, 3 mol equiv) 
and EDC-HCl (1.83 g, 9.557 mmol, 4.8 mol equiv) and the reaction stirred under a nitrogen 
atmosphere overnight. DIPEA (0.68 g, 5.251 mmol, 2.6 mol equiv) was added and the 
Scheme 7: NHS esterification of 6-maleimidohexanoic acid 
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solution stirred for a further 2 hours. The solution was washed with hydrochloric acid (1 M), 
saturated potassium carbonate and brine. Magnesium sulphate was used to dry the organic 
layer and the solvent was removed by rotary evaporation. The product was collected as a 
pale yellow oil (0.609 g, 1.976 mmol, 98 % yield). 
 
1H NMR (400 MHz, CDCl3), ppm: 6.63 (2H, s, ArH), 3.46 (2H, t, J = 7.2 Hz, CH2),  
  2.78 (2H, s, CH2), .54 (2H, t, J = 7.1 Hz, CH2), 1.71 (2H, m, J = 7.6 Hz, CH2),  
  1.56 (2H, m, J = 7.4 Hz, CH2), 1.34 (2H, m, J = 7.8 Hz, CH2) 
13C NMR (400 MHz, CDCl3), ppm: 170.87, 169.17, 168.41, 134.09, 35.25, 30.78, 28.07,  
  25.82, 25.60, 24.07 
MS (ESI, positive mode): calculated [MW]H+ = 309.1, m/z found = 331.1 (Na+ adduct) 
 
2-Cyanoethyl 2-((3aR,4S,7aS)-4,7-Dimethyl-1,3-Dioxo-1,3,3a,4,7,7a-Hexahydro-2H-










Ethanolamine (0.85 g, 0.0139 mol, 1 mol equiv) and maleic anhydride (1.53 g, 0.016 mol, 
1.1 mol equiv) were dissolved in acetic acid (85 mL). The solution was heated to 180 °C 
and refluxed overnight. Once cooled to room temperature the solvent was removed by 
rotary evaporation, producing an oil. DCM (20 mL) was then added and the solution washed 
with hydrochloric acid (1 M), saturated potassium carbonate and brine. Magnesium 
sulphate was used to dry the organic layer and the solvent was removed by rotary 
Scheme 8: Synthesis of compound 8 
 61 
evaporation. The product was collected as a light brown solid (1.349 g, 7.364 mmol,  
53 % yield). 
 
1H NMR (400 MHz, CDCl3), ppm: 6.66 (2H, s, ArH), 4.16 (2H, t, J = 5.3 Hz, CH2),  
  3.73 (2H, t, J = 5.3 Hz, CH2), 1.95 (3H, s, CH3) 
13C NMR (400 MHz, CDCl3), ppm: 170.44, 134.24, 61.43, 36.93, 20.74 
MS (ESI, positive mode): calculated [MW]H+ = 142.0, m/z found = 142.3 
 












Compound 8B (0.75 g, 4.099 mmol, 1 mol equiv) was dissolved in dry acetonitrile (11.5 mL) 
and 2,5-dimethyllfuran (3.0 mL, 6.8 mol equiv) added. The solution was heated to 65 °C 
under a nitrogen atmosphere and left to stir for 6 hours.  A 1H NMR spectrum was taken to 
ensure the reaction had gone to completion. The solvent was then removed by rotary 
evaporation and concentrated ammonium hydroxide (11.5 mL) was then added directly to 
the product and the solution left to stir overnight. The solvent was removed by rotary 
evaporation and the resulting oil acidified with trifluoroacetic acid to pH 1-2. The product 
was extracted with DCM and magnesium sulphate used to dry the organic layer. The solvent 
was removed by rotary evaporation and the product collected as a brown liquid (1.247 g, 
5.255 mmol, 128 % apparent yield).  
Scheme 9: Furan protection of compound 8B by Diels-Alder chemistry 
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1H NMR (400 MHz, CDCl3), ppm: 6.24 (2H, s, ArH), 3.68 (2H, m, J = 1.8 Hz, CH2),  
  3.64 (2H, m, J = 1.8 Hz, CH2), 2.85 (2H, s, ArH), 2.69 (1H, s, OH), 1.62 (6H, s, CH3) 
13C NMR (400 MHz, CDCl3), ppm: 170.85, 134.08, 47.06, 38.62, 37.56, 26.22 
MS (ESI, positive mode): calculated [MW]H+ = 238.1, m/z found = 238.2, 260.2 (Na+  
  adduct) 
 
2-Cyanoethyl 2-((3aR,4S,7aS)-4,7-Dimethyl-1,3-Dioxo-1,3,3a,4,7,7a-Hexahydro-2H-4,7-




Compound 9C (0.06 g, 2.360 x 10-4 mol, 1 mol equiv) was dissolved in dry DCM (2 mL).  
2-cyanoethyl phosphoramidite chloride (0.06 g, 2.360 x 10-4 mol, 1 mol equiv),  
N,N-diisopropylethylamine (0.15 g, 1.180 mmol, 5 mol equiv), DMAP (a few grains) and 
DCM (5 mL) were added and the reaction stirred under nitrogen for 150 minutes. The 
solution was washed with degassed saturated potassium carbonate and brine. A small silica 
column was prepared and the reaction solution loaded. Two fractions were collected using 
a solvent of DCM : triethylamine (95:5). The fractions were combined and the solvent was 
removed by rotary evaporation (0.097 g, 0.2375 mmol, 101 % apparent yield). 
 










Scheme 10: Phosphoramidite synthesis of compound 9C 
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4.2.3 Conjugation of Linker and DNA 
 







Compound 7 (0.6 mg, 1.947 mmol) was dissolved in DMF (30 µL). Stock solutions of  
DNA 1 and DNA 2 (100 µM, 1 ml autoclaved water) were prepared and DMF-linker solution  
(15 µL) was added to each of the prepared DNA stock solutions. The solutions were 
incubated at 37 °C for 90 minutes. The two solutions were then purified by size-exclusion 
chromatography (‘desalting’) using Zetadex resin (8 mL column) and eluted with autoclaved 
water. A total of 10 fractions were collected for each DNA strand and the UV-Vis absorbance 
measured on the NanoDrop spectrophotometer.   
 







The DNA strands to be used were placed in the DNA synthesiser and washed with deblock, 
before the product (compound 10) was hand-coupled to the two strands of pre-synthesised 
DNA. Dry acetonitrile (1 mL) and an activator, 5-ethylthio-1H-tetrazole in acetonitrile (1 mL), 
were added to the phosphoramidite product and the resulting solution split between the two 











































Scheme 12: Conjugation of compound 10 with DNA 
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DNA columns, which were then washed with acetonitrile and oxidiser. The solid support 
beads were removed from the two DNA columns and placed into corresponding vials. 
Concentrated ammonium hydroxide solution (1 mL) was added and the solution heated at 
55 ℃ overnight, to remove the DNA-linker from the solid support beads. Once cooled to 
room temperature, the samples were placed into the centrifuge and spun for 30 minutes at 
2000 x G. The supernatant was removed and purified by size-exclusion chromatography 
(‘desalting’) using a Zetedex column. The fractions produced were then dried by centrifugal 
vacuum concentration at 65 °C for 4 hours before being re-suspended into autoclaved water 
(1000 µL) and quantified by measuring optical absorbance at 260 nm. 
 
4.2.4 Conjugation of DNA-Linker and Protein 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester-DNA Conjugation with Protein 
 
Sup35NM LCys protein in guanidine was thawed on ice, DTT (0.1 mL) added and left for 2 
hours. A PD10 column was then run, using an Elution G buffer; the fluorescence of all the 
fractions was measured. Fractions 1 – 6 were combined, the absorbance re-measured and 
the protein concentration determined.  The protein was split into two samples (1.2 mL each). 
Linker-DNA1 (93.0 µL) was added to one of the samples and linker-DNA2 (58.9 µL) was 
added to the other. The samples were left for 2 hours above ice. Separately, the protein  
(50 µL) was added to PEG-Maleimide (5 µL) and also to a fluorescent chloroacetamide  
(50 µL). LCys-DNA1 (100 µL), LCys-DNA2 (100 µL), a third sample of LCys-DNA1 (50 µL) 
and LCys-DNA2 (50 µL) combined, LCys-PEG-Maleimide (55 µL) and  
LCys-Chloroacetamide (100 µL) were all precipitated by ethanol precipitation. The samples 
were suspended in 9 volumes of cold, 100 % ethanol and reacted at -20 °C for 1 hour. After 
being centrifuged (10 minutes, 15000 x G), the pellet was dried and washed with cold 
ethanol. The ethanol was then aspirated, the sample dried with nitrogen and re-suspended 
in 8 M, fresh urea. All 5 samples were then loaded into a SDS-PAGE gel (12 % 
polyacrylamide) and run for 2 hours. The gel was imaged on the transilluminator to see the 
fluorescent chloroacetamide before being stained with SYBR safe (10,000 x dilution of 
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Figure 40: Trityl of the second synthesis of 
DNA2 
concentrate into 30 mL of SDS-PAGE running buffer) for 30 minutes. After imaging and 
washing in distilled water, Instant Blue was used to stain the gel for 20 minutes, before it 
was imaged. The samples were left at 2 °C for 48 hours and precipitated again via the 
above ethanol precipitation protocol. All 5 samples were then run on an SDS-PAGE gel  
(12 % polyacrylamide) in the same conditions and with the same staining procedure 
previously used.   
 
4.3 Results and Discussion 
 
4.3.1 Synthesis of DNA 
 
The first attempt to synthesise the desired DNA strands failed twice due to a cytosine base 








As a result, the cytosine base was replaced with a fresh bottle of cytosine at a higher 
concentration (1 g dissolved in 10 mL of dry acetonitrile) and fresh bottles of activator and 
oxidant were also used. The synthesis was re-attempted, with no failures and a much better 






Figure 39: Trityl of the second synthesis of 
DNA1 
Figure 38: Trityl of the first synthesis of 
DNA2 




4.3.2 Synthesis of Linkers 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester Linker 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester 
 
This reaction has been carried out twice, using a method adapted from literature75, with the 
product successfully made on both attempts. However, the first reaction produced a low 
yield (30 %) and so the subsequent reaction was slightly altered.  
 
After stirring overnight under a nitrogen atmosphere, the reaction solution still contained 
some starting material.  As a result, DIPEA was added to the reaction between  
6-maleimidohexanoic acid and N-hydroxysuccinimide and stirring continued for a further 
















The first attempt at synthesis followed a literature example73 and was carried out at 170 °C 
and yielded a white, crystalline solid. However, the yield of this reaction was very low  
(18 %) and so subsequent reactions were carried out at 180 °C to increase the yield. The 
NMR spectrum of the product also contained a peak at around 2 ppm, which was 
determined to be part of the structure and not an impurity; it is the addition of an acetyl 




2,5-Dimethylfuran-Maleimide Exo Adduct 
 
The first attempt of this reaction used a reaction temperature of 65 °C and stirred the 
reaction mixture under nitrogen overnight. However, the flask was submerged too far into 
the oil bath, which caused the solvent to evaporate and thus the reaction did not proceed 
to completion as the starting materials solidified; this was confirmed by the NMR spectrum 
obtained.  
Figure 42: 1H NMR of the synthesis of maleimide alcohol (compound 8) 
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The reaction was then repeated and followed by TLC, which showed that the reaction had 
reached completion in 6 hours. The product was obtained as a yellow oil, containing both 
the exo and endo forms of the structure. Subsequent reaction conditions will use 
concentrated ammonium hydroxide and so only the product with the highest stability is 
desired. The endo form of the product has more steric hindrance than the exo form, caused 
by the alkyl chain of the adjoining ring and so in order to degrade the endo product, leaving 
the more stable exo product, the compound was stirred in concentrated ammonium 
hydroxide overnight. The solution was then washed with hydrochloric acid, potassium 
carbonate and brine, with the product collected as a clear oil residue, although in a low 
yield.  
 
A third and fourth attempt at the reaction used a different work-up method, as found in 
literature.73 Once the exo and endo forms of the product had been produced and stirred 
with concentrated ammonium hydroxide solution, the ammonium was removed by rotary 
evaporation. Trifluoroacetic acid was used to acidify the solution and the product then 








Epoxyisoindol-2-yl)ethyl) Diiospropylphosphoramidite   
 
This reaction used a method from literature74, that had been adapted by another member 
of the group. It was found that the ratio of maleimide alcohol : 2-cyanoethyl phosphoramidite 
chloride : DIPEA as stated in the literature (1 : 1 : 5) worked well but a different work-up 
protocol was needed. The phosphorous is prone to oxidation so in order to reduce the 
chance of oxidation, only an aqueous wash was carried out in the hope that the product 
would be purified enough, but an adequate proportion of the phosphorous would remain 
unoxidised. Every solvent used in the washes were also de-gassed. A small silica column 
was then run, eluted with dichloromethane and triethylamine (95 : 5); triethylamine was 
used in a small quantity to help avoid oxidation of the phosphorous and to add basicity to 
the acidic silica used in the column.  
 
The 31P NMR spectrum showed that although some of the phosphorus had oxidised, a large 
proportion of it remained unoxidised and so the product was used in subsequent steps; the 
linker would be in an excess when coupled to the DNA and so the coupling should still be 
effective. 
Figure 44: 31P NMR of the phosphoramidite maleimide alcohol synthesis  
(compound 10) 
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4.3.3 Conjugation of Linker and DNA 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester-DNA Conjugation with DNA 
 
The first three attempts at conjugating the NHS ester to the DNA strands resulted in 
samples that were very concentrated with DNA and linker, resulting in excess linker 
precipitating out of the fractions after they had been purified by size-exclusion 
chromatography (‘desalting’); de-salting removes unwanted ions and small molecules. The 
 fractions were centrifuged (2000 x G for 5 minutes), the supernatant removed and  
re-suspended into deionised water (1 mL). After storage in the freezer, more excess linker 
precipitated from the solution of some of the fraction, so these fractions were washed with 
ethyl acetate (500 µL, three times each), before being purified using the previous protocol.  
 
MS data showed that the conjugations had been unsuccessful as the only peaks visible in 
the spectra were those that corresponded to the DNA strand on its own and not the  
DNA-linker conjugate. DNA 1 has a MW of 6283.2 Da, DNA 2 has a MW of 6261.2 Da and 
the linker was a MW of 194.1; this should have produced DNA1-linker conjugates with MW 
6477.3 Da and DNA2-linker conjugates of MW 6455.3 DA. 
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The UV-Vis spectrum of DNA1 showed fractions 3 and 4 did contain DNA as there was 
clear absorbance at A260, with fraction 4 containing the highest concentration of DNA. 
Fraction 5 did contain some DNA but was also of a lower purity as there were some 
contaminants around A235 and A300; the peak at A235 is likely to have been caused by 
other organic compounds and salts. The spectrum of DNA2 displayed the same results as 

































It was later realised that the mass of linker used in the conjugation attempts had been far 
too high, with a 1000 times excess being used. The mass of linker was reduced to 0.6 mg, 
which produced cleaner UV-Vis data and concentrations that were in the expected range 
for the latter conjugations.  From the UV-Vis spectra, fraction 4 contained the highest 
concentration of DNA for DNA1, whilst for DNA2 fraction 3 contained the highest 
concentration. All of the fractions for both DNA1 and DNA2, exhibited moderate purity as 

























































Figure 46: UV-Vis spectra of the linker-DNA conjugates from the first conjugation 































As there was a delay in obtaining some MS data confirming whether the linker had 
conjugated with the DNA, the Kaiser test was also carried out on the latter reaction attempts. 
A positive result, in which the solution turns blue, would have indicated a free amine was 
present but when carried out, the solution remained colourless. This indicated that the 



















































Figure 47: UV-Vis spectra of the linker-DNA conjugates from the latest conjugation 




Phosphoramidite Maleimide Alcohol Conjugation with DNA 
 
The conjugation of the phosphoramidite maleimide alcohol with DNA has been attempted 
twice, with both attempts being unsuccessful. The UV-Vis data collected indicated fractions 
3 and 4 contained high concentrations of DNA for DNA1. Although the spectrum implied 
these fractions had reasonable purity, fraction 5 could have been contaminated as a change 
in the expected spectral shape indicates contaminates. For DNA2, fractions 3, 4 and 5 all 








































































The DNA 1 strand has a MW of 6101.03 Da and DNA 2 has a MW of 6079.05 Da. The linker 
would have a MW of 315.15 Da, resulting in a DNA1-linker conjugate with a MW of  
6414.08 Da and a DNA2-linker conjugate with a MW of 6394.10 Da. However, the MS data 
showed that the linker had not attached to the DNA and only the DNA remained in the 
solution. This could be due to a number of differing reasons. Firstly, the phosphorous would 
have continued to oxidise whilst the 31P NMR spectrum was obtained and during the time 
when the DNA strands were washed with acetonitrile and deblock; these washes were 
carried out in order to remove the 4,4’-dimethoxytrityl protecting group on the 5’-hydroxyl of 
the DNA strands. There may also have been issues with the columns containing the DNA 
strands as they had been stored in the freezer.  




4.3.4 Conjugation of DNA-Linker and Protein 
 
6-Maleimidohexanoic Acid N-Hydroxysuccinimide Ester-DNA Conjugation with Protein 
 
It should be noted that this experiment was run before MS data was obtained for the 
conjugation of the linker (linker 2A) and DNA. MS data has since shown that the 
conjugation of the linker and DNA was unsuccessful and consequently this work would not 
have attained any beneficial results.  
 
The gel produced showed that the conjugation of DNA-linker with Sup35NM LCys was 
unsuccessful. Conjugation of the protein to the fluorescent chloroacetamide was 
successful, as the gel showed three bands; these three bands represented conjugation to 
the protein monomer, protein dimer and also no conjugation. However, after staining with 
SYBR safe, the only bands visible for DNA were right at the bottom of the gel, corresponding 
to just the DNA-linker. It would be expected that there would also be a conjugation band 
higher up on the gel, which would represent DNA-LCys. Likewise, once the gel was stained 
with Instant Blue, the only visible bands corresponded to the protein monomer and there 











The above protocol was determined to be the most suitable produced so far. A previous 
attempt of the conjugation followed a slightly different method, as described below; these 
Figure 50: The gel after 
DNA staining 
Figure 51: The gel after 
protein staining 
Figure 52: The gel viewed 
on the transilluminator 
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conjugations have been carried out in order to find the most suitable conditions and method 
for future conjugations.  
 
A PD10 column was run, using an Elution G buffer; in order to exchange the buffer that the 
protein was in, and also to remove the DTT used to reduce the cysteine on the protein. The 
protein concentration was determined and thus samples of LCys-DNA1 and LCys-DNA2 
were prepared, comprising of protein, DNA, DTT and Elution G buffer. These two samples 
were combined and then ran through PD10 columns and UV-Vis absorbance collected.  
However, during these steps it was assumed the reduction of the thiol-group on the cysteine 
residue by DTT and the conjugation of DNA-linker to the protein were both immediate; future 
conjugations will allow time for these reactions to occur before the subsequent steps are 
carried out. The absorbance was also too high to be calculated and thus the final 
conjugated protein concentration was not estimated; this would mean the molar equivalents 
of DNA and linker would not be accurate and hence the reaction would not be repeatable. 
 
Samples were also prepared to be run on an SDS-PAGE gel (12 % polyacrylamide) with 
the following quantities, 
 
LCys-DNA1:  Protein (50 µL), DNA1 (19.16 µL) ,DTT (10 µL), Elution G buffer (20.84 µL) 
LCys-DNA2:  Protein (50 µL), DNA2 (10.24 µL), DTT (10 µL), Elution G buffer (29.76 µL) 
LCys-DNA1-DNA2:  Protein (50 µL), DNA1 (9.58 µL), DNA2 (5.12 µL), DTT (10µL), 
Elution G buffer (25.30 µL) 
 
The samples were precipitated by the ethanol precipitation protocol before being loaded 
onto the gel. The gel was run for 2 hours and then stained with SYBR safe and Instant Blue.  
It was evident from the gel that the conjugation did not work. From the SYBR safe stain, 
there was a thin band across all three samples lane where the DNA was; this corresponded 
to the DNA itself which, as it is so small, ran to the end of the gel. There were no visible 
bands representative of the protein-DNA conjugation.  Similarly, the stain with Instant Blue 
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An amyloid formation assay was also run over ~72 hours, using a 96 well microplate. The 
well plate contained varying proportions of Sup35NM LCys and wild type (WT) protein, as 
well as some wells containing ThT dye, as shown below in figure 55; ThT was added in 
order to study the kinetics of fibril formation, whilst the wells that contained only the eluted 
solution would enable AFM imaging of the fibrils. However, upon discovery that the 
conjugation was unsuccessful from the SDS-PAGE gel, downstream experiments  
(ThT assay, AFM imaging) were aborted, but their initial impression was to confirm there 
was no change in formation compared to that of the wild type protein.  
 
During the buffer exchange of Sup35NM LCys into the fibril formation buffer, 2 peaks were 
observed when the A280 nm value was measured. As a result, both protein eluents were 
used. However, as the conjugation did not work, the first peak shown in the A280 nm 
measurement would have been representative of the protein, whilst the second peak would 
have corresponded to just the linker-DNA eluting separately. Consequently, the fibrils that 
could be seen from the amyloid formation assay were fibrils of the wild type protein 
aggregating on its own. This, coupled with the SDS-PAGE gel, indicated that the conjugates 
had not been produced and consequently, the ThT assay was stopped and AFM imaging 
of the fibrils was not carried out.  






In general, the synthesis of both the chemical linkers has been achieved, although with 
varying degrees of success. The synthesis of linker 2A, shown below in figure 56,  
6-maleimidohexanoic acid N-hydroxysuccinimide ester, was completed with the structure 
of the linker confirmed by both 1H and 13C NMR spectra and MS data. Subsequently, the 
linker was conjugated to DNA strands, that had been purchased from IDT technologies. 
Despite the UV-Vis absorbance graphs and the Kaiser test indicating that the conjugation 
had occurred, MS data repeatedly showed the conjugation had been unsuccessful. The 
conjugation of the linker 2A-DNA with the protein had been carried out before the MS data 


















Figure 56: The two chemical linkers 
Left: Compound 7, which is linker 2A 
Right: Compound 10, which is linker 2B 
 
Figure 55: The 96 well microplate 
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Linker 2B, shown above in figure 56, was also partially successful. The three-step 
synthesis was undertaken and NMR spectra showed that the desired molecule had been 
produced at each step; MS data also confirmed the presence of the target molecules for 
the first two reactions. Nevertheless, when the linker was hand-coupled to the synthesised 
DNA strands, the coupling was unsuccessful, as confirmed by MS data. Consequently, the 




















In summary, this research set out to synthesise two different chemical linkers, which would 
be utilised to conjugate a known amyloid-forming protein and a strand of DNA. Chapter 2 
focused on the synthesis and characterisation of two maleimide linkers, whose structure 
only differed in the length of the carbonyl chain between the nitrogen-containing aromatic 
group and the maleimide ring. Originally the project set out to synthesise only linker 1A. 
However, due to multiple unsuccessful attempts a new method was devised, producing the 
bigger linker 1B; the structures of these are shown below in figure 57 for reference. Once 
NMR spectra and MS data showed whether the desired product had been produced, 
conjugations with the protein were carried out; MS data showed protein-linker conjugates 









Chapter 3 reviews the methods used to conjugate linker 1B synthesised in chapter 2 with 
a Waltz peptide, Ac-CGSGHYFNIF-NH2.  Many attempts at the conjugation were carried 
out before the method was refined and the presence of conjugates were seen by TLC 
analysis and later by MS data. Once achieved, the reaction was attempted again on a larger 
scale in the hope to isolate the conjugate in order for purification and more analysis to be 

















Figure 57: The two maleimide chemical linkers 
Left: Linker 1A (compound 4) 
Right: Linker 1B (compound 5) 
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Chapter 4 then discussed the techniques to produce and characterise two phosphoramidite 
maleimide linkers, whose structures were slightly different. The first method led to the 
successful synthesis of Iinker 2A (compound 7), shown below in figure 58, which was thus 
bonded to a strand of DNA by a solution-based method. NMR spectra was used to check 
the structure of the linker, before UV-Vis measurements confirmed the presence of the DNA 
and were used to calculate its concentration. Once completed, the linker-DNA strands were 
conjugated to a protein, Sup35NM LCys, with polyacrylamide gels, MS data and analysis 
of 96 well microplates used to confirm the presence of the conjugates and to monitor the 
growth of amyloid fibrils. The first attempts at the conjugation was unsuccessful, which led 
to method development to find the most suitable conditions and method for the succeeding 
conjugations. Linker 2B (compound 10), shown below in figure 58, was successfully 
synthesised, but unfortunately the conjugation with the DNA was unsuccessful. NMR 
spectra confirmed that the linker had been produced, although the phosphorous atom was 
present in both its oxidised and unoxidised state, with more oxidised phosphorous present. 
As a result, when coupled to the DNA, using solid beads containing the DNA, the reaction 
was unsuccessful. UV-Vis measurements confirmed the presence of the DNA, but MS data 






























Figure 58: The two chemical linkers 
Left: Linker 2A (compound 7) 
Right: Linker 2B (compound 10) 
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5.2 Future Work 
 
If this research was continued, the attempts at synthesising linker 1A would have been 
pursued. More conjugations of linker 1B would have also been carried out, with analysis of 
amyloid formation assays incorporating the use of ThT dye to monitor the kinetics and 
image any fibrils produced. If achieved, variation of the DNA strands would have also been 
investigated; differing the length and sequence of DNA strands could alter the assembly of 
Sup35NM LCys into fibrils, as well as the ratio of protein to linker and DNA strand. 
 
Future work of this project would continue the analysis of the phosphoramidite maleimide 
linker 2A with DNA strands and protein. The conjugation of DNA-linker with protein would 
be continued, with the level of crosslinking between the complementary DNA strands 
controlled by altering the amount of fibrils in the amyloid that are covalently bonded to the 
linker and thus to a DNA strand, once of the conditions of the conjugation had been 
optimised.  
 
Furthermore, the conjugation of linker 1B with the Waltz peptide would be continued. The 
conjugates of the linker and peptide were seen in MS data and future work would thus 
repeat this conjugation on a larger scale for more analysis to be continued. If successful, a 
linker-peptide conjugate would be isolated, purified and, once its presence confirmed by 
MS, AFM imaging would be carried out to study the formation and assembly of the linker-
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